U.S. markets open in 7 hours 19 minutes

BeiGene, Ltd. (BGNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
311.97-2.03 (-0.65%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close314.00
Open321.09
Bid0.00 x 1100
Ask0.00 x 800
Day's Range309.97 - 327.39
52 Week Range155.16 - 388.97
Volume304,122
Avg. Volume262,267
Market Cap28.688B
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-13.47
Earnings DateAug 07, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est362.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer
    Business Wire

    China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer

    BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its PARP inhibitor pamiparib has received conditional approval from the China National Medical Products Administration (NMPA) for the treatment of patients with germline BRCA (gBRCA) mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy. The new drug application was previously granted priority review by the Center for Drug Evaluation (CDE) in July 2020. BeiGene is preparing to launch pamiparib this month.

  • BeiGene Reports First Quarter 2021 Financial Results
    Business Wire

    BeiGene Reports First Quarter 2021 Financial Results

    BeiGene reported recent business highlights, anticipated upcoming milestones, and financial results for the first quarter of 2021.

  • BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies
    Benzinga

    BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies

    BeiGene Ltd (NASDAQ: BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against Johnson & Johnson's (NYSE: JNJ) Imbruvica (ibrutinib) in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The data is based on 415 of 652 patients followed for a minimum of 12 months. The planned final analysis is expected in 2022. Brukinsa met the primary endpoint of the trial, demonstrating non-inferiority in objective response rate (ORR) vs. ibrutinib by investigator assessment and a numerically higher ORR but not statistically significant improvement by the independent review committee. The trial also met a prespecified secondary endpoint related to safety, and Brukinsa demonstrated a statistically significant lower risk of atrial fibrillation or flutter versus ibrutinib. BeiGene plans to present these data at an upcoming major medical conference. Price Action: BGNE shares are up 9.2% at $353.25 during market trading hours on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaEli Lil­ly Aban­dons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease IndicationsUS To Share Up To 60M AstraZeneca COVID-19 Vaccine Doses© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.